XML 72 R55.htm IDEA: XBRL DOCUMENT
v3.19.1

Arrangements with Symphony Icon, Inc. (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Mar. 31, 2017 | Sep. 30, 2016 | Apr. 30, 2015 | Dec. 31, 2014 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Jul. 30, 2012 | Jul. 30, 2010 | Jun. 15, 2007
Arrangements with Symphony Icon Inc [Abstract] |  |  |  |  |  |  |  |  |  |
Holdings Contribution To Icon |  |  |  |  |  |  |  |  |  | $ 45,000
Lexicon Sold Shares To Holdings |  |  |  |  |  |  |  |  |  | 1,092,946
Lexicon Received Cash From Holdings |  |  |  |  |  |  |  |  |  | $ 15,000
Lexicon Paid Holdings Cash |  |  |  |  |  |  |  |  | $ 10,000 |
Symphony Fair Value Of Base And Contingent Payments |  |  |  |  |  |  |  |  | $ 45,600 |
Symphony Base Payment Discount Rate |  |  |  |  |  |  |  |  | 14.00% |
Symphony Contingent Payment Discount Rate |  |  |  |  |  |  |  |  | 18.00% |
Symphony Base Payment In Shares |  |  |  |  |  |  |  | 1,891,074 |  |
Symphony Base Payment Obligation |  |  |  |  |  |  |  | $ 35,000 |  |
Symphony Contingent Payment Maximum |  |  |  |  |  |  |  |  | $ 45,000 |
Symphony Contingent Payment Percentage |  |  |  |  |  |  |  |  | 50.00% |
Symphony Regulatory Approval Payment |  |  |  |  |  |  |  |  | $ 15,000 |
Symphony Regulatory Approval Reduction Percentage |  |  |  |  |  |  |  |  | 50.00% |
Symphony Regulatory Approval Percentage Limit |  |  |  |  |  |  |  |  | 50.00% |
Symphony Payment In Stock Limitation |  |  |  |  |  |  |  |  | 50.00% |
Symphony Contingent Payment In Cash | $ 10,500 | $ 3,200 | $ 750 | $ 5,800 |  | $ 10,499 |  |  |  |
Symphony Amendment Buyout |  | $ 21,000 |  |  |  |  |  |  |  |
Symphony Contingent Payment in Shares | 659,905 |  |  | 666,111 |  |  |  |  |  |
Symphony Contingent Payment Total |  |  |  | $ 11,500 |  |  |  |  |  |
Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability |  |  |  |  | $ 0 | $ 2,101 | $ (703) |  |  |

X
- Definition Arrangements with Symphony Icon Inc [Abstract] + References No definition available. + Details
Name: | lxrx_ArrangementsWithSymphonyIconIncAbstract
Namespace Prefix: | lxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations. + References No definition available. + Details
Name: | lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition On June 15, 2007, Symphony Icon Holdings LLC contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs. + References No definition available. + Details
Name: | lxrx_HoldingsContributionToIcon
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the cash paid to Holdings. + References No definition available. + Details
Name: | lxrx_LexiconPaidHoldingsCash
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. + References No definition available. + Details
Name: | lxrx_LexiconReceivedCashFromHoldings
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs. + References No definition available. + Details
Name: | lxrx_LexiconSoldSharesToHoldings
Namespace Prefix: | lxrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This represents the acquisition date fair value. + References No definition available. + Details
Name: | lxrx_SymphonFairValueOfBaseAndContingentPayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition In July 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings. In September 2016, Lexicon entered into an amendment to this agreement. This represents the buyout amount that Lexicon will pay Holdings in the event Lexicon receives regulatory approval in the U.S. for the marketing and sale of telotristat ethyl, such buyout amount to be in lieu of any remaining payments which may be or become payable to Holdings under the Purchase Option Agreement. + References No definition available. + Details
Name: | lxrx_SymphonyAmendmentBuyout
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This represents the acquisition date discount rate for the base payment. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentDiscountRate
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the 13,237,519 shares of common stock issued to designees of Holdings on July 30, 2012 in satisfaction of the base payment obligation. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentInShares
Namespace Prefix: | lxrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the $35 million base payment obligation that was paid in common stock. + References No definition available. + Details
Name: | lxrx_SymphonyBasePaymentObligation
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments. The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This represents the acquisition date discount rate for the contingent payments. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentDiscountRate
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contingent payments to Symphony Icon Holdings in the form of cash. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentInCash
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the maximum amount for any contingent payment. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentMaximum
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the percentage of consideration received that will be paid to Holdings. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentPercentage
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contingent payments to Symphony Icon Holdings, in total. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentTotal
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent payments to Symphony Icon Holdings in the form of stock. + References No definition available. + Details
Name: | lxrx_SymphonyContingentPaymentinShares
Namespace Prefix: | lxrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The contingent payments to Holdings may be paid in cash or a combination of cash and common stock, in Lexicon's discretion, provided that no more than 50% of any payment will be paid in common stock. + References No definition available. + Details
Name: | lxrx_SymphonyPaymentInStockLimitation
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. This represents the payment that will be made upon regulatory approval. + References No definition available. + Details
Name: | lxrx_SymphonyRegulatoryApprovalPayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval. This represents the percentage by which proceeds of Licensing Transactions must exceed regulatory approval payments in order for Lexicon to have an obligation to make subsequent contingent payments. + References No definition available. + Details
Name: | lxrx_SymphonyRegulatoryApprovalPercentageLimit
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. This represents the percentage reduction of the regulatory approval payment by previous contingent payments. + References No definition available. + Details
Name: | lxrx_SymphonyRegulatoryApprovalReductionPercentage
Namespace Prefix: | lxrx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant